RHI Magnesita (RHIM) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
3 Feb, 2026Executive summary
Revenue was stable at €1,728 million, as M&A offset a 3% decline in sales volumes and 4% lower pricing, with demand subdued except India.
Adjusted EBITA declined 5% to €190 million, margin at 11.0%, with strong cash conversion at 123%.
Adjusted EPS rose 2% to €2.59, supported by FX gains and lower finance charges.
M&A activity continues to drive growth, with 10 acquisitions since Dec 2021 and Resco Group acquisition pending.
Fatal safety incident in China prompted a global safety review.
Financial highlights
Revenue: €1,728 million (flat year-over-year); Adjusted EBITA: €190 million (down 5%); Adjusted EPS: €2.59 (up 2%).
Adjusted EBITA margin: 11.0% (down 60bps); gross margin improved to 24.1%.
Record operating cash flow of €233 million, with cash conversion at 123% of EBITA.
Dividend per share increased to €0.60 (+9% YoY), in line with policy.
Net debt: €1,274 million; liquidity: €1,405 million.
Outlook and guidance
Full-year adjusted EBITA guidance of at least €410 million reaffirmed, with H2 expected to benefit from seasonality and delayed project deliveries.
No material recovery in market-driven demand expected in H2 2024; volume growth to come from project deliveries and seasonality.
Working capital intensity targeted at ~24% for the full year.
Capex guidance for 2024 revised down to €135 million due to digital spend reclassification.
Net debt to pro forma adjusted EBITDA expected to remain within 2.0–2.5x for periods of compelling M&A.
Latest events from RHI Magnesita
- Cost actions and M&A drove H2 recovery in 2025, supporting a cautious 2026 outlook.RHIM
Q4 20252 Mar 2026 - Margins exceeded guidance despite weak demand; EBITA outlook trimmed amid persistent overcapacity.RHIM
Q3 2024 TU15 Jan 2026 - Solid 2024 results and margin gains despite weak demand; modest growth seen for 2025.RHIM
H2 202416 Dec 2025 - Weak Q1, overcapacity, and trade risks make H2 recovery vital for guidance.RHIM
Q1 2025 TU21 Nov 2025 - Revenue and margins fell on weak demand and pricing, but H2 recovery is expected.RHIM
H1 202516 Nov 2025 - Cost savings and RESCO integration drove margin recovery despite weak demand.RHIM
Q3 2025 TU10 Nov 2025